Author:
Ravasio Roberto,Mazzi Silvio,Esposito Maria,Fiorino Gionata,Migliore Alberto
Abstract
Patients’ quality of life impairment together with a heavy burden to the National Health Service (NHS) and society are caused by chronic inflammatory diseases. Their treatment substantially improved with the advent of biological drugs (such as adalimumab), but these drugs are very expensive. At present, the patent protection of adalimumab (Humira®) has expired, and a biosimilar (Hyrimoz®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact (DBI) analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings). The time horizon in the analysis model is five years. The initial overall number of patients treated with adalimumab is estimated (based on the Italian population, the disease prevalence rates, the proportion of patients under treatment and adalimumab market share) and then kept constant in time. However, the model assumes that, year by year, patients in treatment with the originator will partly switch to the biosimilar (based on a prudent estimate of the uptake rate), while (due to a bolder estimate) a larger share of naïve patients will directly start with the biosimilar. Thanks to such assumptions, total number of patients treated with adalimumab (separately with the originator and with the biosimilar) is estimated, together with the respective total costs. According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €260 millions for the Italian NHS.
Reference16 articles.
1. De Vol R, Bedroussian A. An unhealthy America: The economic burden of chronic disease. The Milken Institute, 2007. Disponibile sul sito: http://assets1c.milkeninstitute.org/assets/Publication/ResearchReport/PDF/chronic_disease_report.pdf Accesso: Marzo 2019.
2. Uhlig T, Loge JH, Kristiansen IS et al. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241-7.
3. Lundkvist J, Kastang F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ. 2008;8 Suppl 2:549-60.
4. Marcellusi R, Viti R, Capone A et al. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. PharmacoEcon Ital Res Artic. 2014; online, DOI: 10.1007/s40276-014-0023-9
5. Allegri M, Lucioni C, Mazzi S et al. Il costo sociale del dolore cronico in Italia. Glob Reg Health Technol Assess. 2014; online, DOI: 10.5301/GRHTA.5000187
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献